Sartorius Unveils Modular Eveo Platform Aiming to Slash CAR-T Manufacturing Costs by Ninety Percent and Quadruple Output

New Sartorius Eveo platform quadruples cell therapy output and cuts costs by 90%. Explore the future of automated CAR-T manufacturing.

By: AXL Media

Published: Mar 18, 2026, 8:33 AM EDT

Source: Information for this report was sourced from Sartorius

Industrializing the Future of Autologous Medicine

The life science group Sartorius has introduced a fundamentally new architecture for the production of personalized cell therapies, targeting the structural inefficiencies that have long plagued the advanced therapeutics market. The Eveo Cell Therapy Platform is a modular, integrated system that manages the entire lifecycle of autologous production, from initial cell selection to final formulation and quality control. According to René Fáber, a member of the Sartorius Executive Board, the goal of this innovation is to move beyond the complex and capacity-constrained manufacturing models that currently limit life-saving CAR-T treatments to a small fraction of eligible patients. By integrating raw materials with automated hardware and software, the platform seeks to shorten the critical "vein-to-vein" time for individuals facing aggressive diseases.

Overcoming the Traditional Greenfield Investment Barrier

Conventional manufacturing for cell therapies typically requires massive "greenfield" investments, involving the construction of purpose-built facilities, extensive staff recruitment, and multi-year buildup phases. Despite these high costs, Sartorius reports that roughly 60 percent of regulatory disruptions in the sector are caused by process-related failures. The Eveo platform addresses these challenges by offering a compact, closed-system design that can be implemented within existing facilities using current staff. This flexibility allows for operations in lower-classification environments and supports both centralized and decentralized manufacturing models, effectively lowering the barrier to entry for hospitals and smaller biotech firms looking to scale their production capabilities.

Achieving a Fourfold Increase in Clinical Throughput

The efficiency gains promised by the new platform are driven by a multi-parallel configuration that allows a single operator to manage eight patient batches simultaneously. In traditional cleanroom setups, the same space would typically yield only two batches in the same timeframe. Through successful pilot testing with industry partners like ElevateBio, Sartorius demonstrated that the Eveo system can produce more than 350 doses per year within a footprint that currently yields only 100. This nearly fourfold increase in output is paired with financial modeling that sugg...